The impact of cancer metastases on COVID-19 outcomes: A COVID-19 and Cancer Consortium registry-based retrospective cohort study.
COVID-19
cancer
metastasis
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
20 Feb 2024
20 Feb 2024
Historique:
revised:
20
11
2023
received:
26
06
2023
accepted:
20
12
2023
medline:
20
2
2024
pubmed:
20
2
2024
entrez:
20
2
2024
Statut:
aheadofprint
Résumé
COVID-19 can have a particularly detrimental effect on patients with cancer, but no studies to date have examined if the presence, or site, of metastatic cancer is related to COVID-19 outcomes. Using the COVID-19 and Cancer Consortium (CCC19) registry, the authors identified 10,065 patients with COVID-19 and cancer (2325 with and 7740 without metastasis at the time of COVID-19 diagnosis). The primary ordinal outcome was COVID-19 severity: not hospitalized, hospitalized but did not receive supplemental O Compared to patients without metastasis, patients with metastases have increased hospitalization rates (59% vs. 49%) and higher 30 day mortality (18% vs. 9%). Patients with metastasis to bone, lung, liver, lymph nodes, and brain have significantly higher COVID-19 severity (adjusted odds ratios [ORs], 1.38, 1.59, 1.38, 1.00, and 2.21) compared to patients without metastases at those sites. Patients with metastasis to the lung have significantly higher odds of 30-day mortality (adjusted OR, 1.53; 95% confidence interval, 1.17-2.00) when adjusting for COVID-19 severity. Patients with metastatic cancer, especially with metastasis to the brain, are more likely to have severe outcomes after COVID-19 whereas patients with metastasis to the lung, compared to patients with cancer metastasis to other sites, have the highest 30-day mortality after COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19 can have a particularly detrimental effect on patients with cancer, but no studies to date have examined if the presence, or site, of metastatic cancer is related to COVID-19 outcomes.
METHODS
METHODS
Using the COVID-19 and Cancer Consortium (CCC19) registry, the authors identified 10,065 patients with COVID-19 and cancer (2325 with and 7740 without metastasis at the time of COVID-19 diagnosis). The primary ordinal outcome was COVID-19 severity: not hospitalized, hospitalized but did not receive supplemental O
RESULTS
RESULTS
Compared to patients without metastasis, patients with metastases have increased hospitalization rates (59% vs. 49%) and higher 30 day mortality (18% vs. 9%). Patients with metastasis to bone, lung, liver, lymph nodes, and brain have significantly higher COVID-19 severity (adjusted odds ratios [ORs], 1.38, 1.59, 1.38, 1.00, and 2.21) compared to patients without metastases at those sites. Patients with metastasis to the lung have significantly higher odds of 30-day mortality (adjusted OR, 1.53; 95% confidence interval, 1.17-2.00) when adjusting for COVID-19 severity.
CONCLUSIONS
CONCLUSIONS
Patients with metastatic cancer, especially with metastasis to the brain, are more likely to have severe outcomes after COVID-19 whereas patients with metastasis to the lung, compared to patients with cancer metastasis to other sites, have the highest 30-day mortality after COVID-19.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : NIH T32CA009515-37
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016056
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046592
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA068485
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA123456
Pays : United States
Organisme : NCI NIH HHS
ID : T32-CA236621
Pays : United States
Informations de copyright
© 2024 American Cancer Society.
Références
Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918. doi:10.1016/s0140-6736(20)31187-9
Seneviratne SL, Wijerathne W, Yasawardene P, Somawardana B. COVID-19 in cancer patients. Trans R Soc Trop Med Hyg. 2022;116(9):767-797. doi:10.1093/trstmh/trac015
World Health Organization. Cancer Fact Sheet; 2022. Accessed July 15, 2022. https://www.who.int/news-room/fact-sheets/detail/cancer
Bilen MA, Shabto JM, Martini DJ, et al. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. BMC Cancer. 2019;19(1):857. doi:10.1186/s12885-019-6073-7
Nieblas-Bedolla E, Zuccato J, Kluger H, Zadeh G, Brastianos PK. Central nervous system metastases. Hematol Oncol Clin North Am. 2022;36(1):161-188. doi:10.1016/j.hoc.2021.08.004
Jamil A, Kasi A. Lung Metastasis. In: StatPearls [Internet]. StatPearls Publishing; 2024. PMID: 31971751.
Reckamp KL, Redman MW, Dragnev KH, et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A. J Clin Oncol. 2022;40(21):2295-2306. doi:10.1200/jco.22.00912
Elkrief A, Wu JT, Jani C, et al. Learning through a pandemic: the current state of knowledge on COVID-19 and cancer. Cancer Discov. 2022;12(2):303-330. doi:10.1158/2159-8290.cd-21-1368
Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21(8):1023-1034. doi:10.1016/s1470-2045(20)30388-0
Mohiuddin M, Kasahara K. Cancer metastasis may increase COVID-19 mortality: suitable targets required to impede cancer metastasis. J Infect Public Health. 2022;15(2):153-155. doi:10.1016/j.jiph.2021.12.004
Wong YNS, Sng CCT, Ottaviani D, et al. Systemic anticancer therapy and metastatic cancer are independent mortality risk factors during two UK waves of the COVID-19 pandemic at University College London Hospital. Cancers. 2021;13(23):6085. doi:10.3390/cancers13236085
Desai A, Warner J, Kuderer N, et al. Crowdsourcing a crisis response for COVID-19 in oncology. Nature Cancer. 2020;1(5):473-476. doi:10.1038/s43018-020-0065-z
Rubinstein SM, Steinharter JA, Warner J, Rini BI, Peters S, Choueiri TK. The COVID-19 and Cancer Consortium: a collaborative effort to understand the effects of COVID-19 on patients with cancer. Cancer Cell. 2020;37(6):738-741. doi:10.1016/j.ccell.2020.04.018
Harris PA, Taylor R, Minor BL, et al. The REDCap Consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi:10.1016/j.jbi.2019.103208
Abidi M, Aboulafia DM, Accordino MK, et al. A systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance. Cancer Cell. 2020;38(6):761-766. doi:10.1016/j.ccell.2020.10.022
Shyr Y, Berry LD, Hsu CY. Scientific rigor in the age of COVID-19. JAMA Oncol. 2021;7(2):171-172. doi:10.1001/jamaoncol.2020.6639
Bakouny Z, Labaki C, Grover P, et al. Interplay of immunosuppression and immunotherapy among patients with cancer and COVID-19. JAMA Oncol. 2022;9(1):128. doi:10.1001/jamaoncol.2022.5357
French B, Shotwell MS. Regression models for ordinal outcomes. JAMA. 2022;328(8):772-773. doi:10.1001/jama.2022.12104
Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34(14):1652-1659. doi:10.1200/jco.2015.65.7270
Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer. 2019;19(1):1091. doi:10.1186/s12885-019-6311-z
Grivas P, Khaki AR, Wise-Draper TM, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021;32(6):787-800. doi:10.1016/j.annonc.2021.02.024
Marta GN, Bonadio RC, Sejas ONE, et al. Outcomes and prognostic factors in a large cohort of hospitalized cancer patients with COVID-19. JCO Global Oncology. 2021(7):1084-1092. doi:10.1200/go.21.00087
Addeo A, Obeid M, Friedlaender A. COVID-19 and lung cancer: risks, mechanisms and treatment interactions. J Immunother Cancer. 2020;8(1):e000892. doi:10.1136/jitc-2020-000892
Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021;9(3):e002266. doi:10.1136/jitc-2020-002266
Casaluce F, Gridelli C. Narrative review of lung cancer treatment at the time of COVID-19 pandemia: pitfall and issues. Transl Lung Cancer Res. 2021;10(1):475-482. doi:10.21037/tlcr-20-640
Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255-2273. doi:10.1056/nejmra2026131
Bian DJH, Sabri S, Abdulkarim BS. Interactions between COVID-19 and lung cancer: lessons learned during the pandemic. Cancers (Basel). 2022;14(15):3598. doi:10.3390/cancers14153598
Friese CR, Choueiri TK, Duma N, et al. Care without a compass: including patients with cancer in COVID-19 studies. Cancer Cell. 2021;39(7):895-896. doi:10.1016/j.ccell.2021.04.006
Choueiri TK, Labaki C, Bakouny Z, et al. Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium. Lancet Reg Health Am. 2023:19.
Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 Omicron in China. Nature Medicine. 2022;28(7):1468-1475. doi:10.1038/s41591-022-01855-7
Núñez A, Sreeganga SD, Ramaprasad A. Access to healthcare during COVID-19. Int J Environ Res Public Health. 2021;18(6):2980. doi:10.3390/ijerph18062980